Clinical Epidemiology in Contemporary Patients With Myelofibrosis.

NCT06533813 · tracked via the Priya Life Science Germany tracker

Sponsor

FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS

Phase

Observational

Started

2024-10-14

Last updated

2026-07-09

Condition(s) studied

Myelofibrosis

Study summary

Multicenter retrospective and prospective European observational study. At each site, all consecutive patients with a 2016- or 2022 World Health Organization (WHO) confirmed diagnosis of myelofibrosis (MF) established from 01/01/2018 to 31/12/2027 will be enrolled into the study. Yearly follow-up updates will be scheduled until the end of data collection on 31/12/2028 or until the last available patient visit, whichever comes first. At least 1 year of follow-up will be ensured from the last patient enrolled.

Eligibility

Sex

ALL

Min age

18 Years

Max age

100 Years

Healthy volunteers

Inclusion Criteria: * Diagnosis of primary myelofibrosis (PMF) or secondary (i.e., post-ET/PV MF) myelofibrosis according to 2016- or 2022-WHO criteria ascertained between 01/01/2018 and 31/12/2027 * Age ≥ 18 years * Signed informed consent where applicable, in line with current European General Data Protection Regulation (GDPR) directives Exclusion Criteria: * Diagnosis of early/prefibrotic primary myelofibrosis * Concurrent participation to interventional clinical trials in MF

Primary outcome measure(s)

Overall survival according to the presence of cytopenias at diagnosis — At diagnosis during the baseline
Obtained by medical health records normally filled out in clinical practice

Trial sites (27)

Facility	City	Region	Status
Hematology Center after Prof.R.H. Yeolyan	Yerevan	Armenia	Recruiting
University Hospital Halle Department of Hematology/Oncology	Halle	Germany	Not Yet Recruiting
University Medicine Hannover	Hanover	Germany	Recruiting
University Clinic for Hematology, Oncology, Hemostaseology and Palliative Care Johannes Wesling Medical Center Minden UKRUB, University of Bochum	Minden	Germany	Recruiting
A.S.O. SS. Antonio e Biagio e C.Arrigo, SC Ematologia	Alessandria	Italy	Recruiting
ASST Papa Giovanni XXIII, SC Ematologia	Bergamo	Italy	Recruiting
Policlinico S. Orsola - Malpighi, Unità di Ematologia	Bologna	Italy	Recruiting
Azienda Ospedaliero - Universitaria "Policlinico Vittorio Emanuele" - PO Gaspare Rodolico, Dipartimento di ematologia con Trapianto di midollo Osseo	Catania	Italy	Recruiting
AOU Careggi di Firenze, Divisione di Ematologia	Florence	Italy	Recruiting
ASST Grande Ospedale Metropolitano Niguarda, Divisione di Ematologia	Milan	Italy	Recruiting
Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Ematologia	Milan	Italy	Recruiting
Ospedale San Raffaele, Unità Operativa di Ematologia e Trapianto Midollo Osseo	Milan	Italy	Recruiting
Fondazione IRCCS San Gerardo dei Tintori	Monza	Italy	Recruiting
Azienda Ospedaliera Universitaria Federico II, Divisione di Ematologia	Naples	Italy	Recruiting
Azienda Ospedaliero Universitaria Maggiore della Carità, SCDU Ematologia	Novara	Italy	Recruiting
Fondazione IRCCS Policlinico San Matteo, Divisione di Ematologia	Pavia	Italy	Recruiting
Fondazione Policlinico Universitario A. Gemelli - Università Cattolica del Sacro Cuore, UCSC Ematologia	Roma	Italy	Recruiting
Policlinico Umberto I, Dipartimento Ematologia, Oncologia e Dermatologia	Roma	Italy	Recruiting
A.O.U. Città della Salute e della Scienza di Torino - Ospedale Molinette- S.C. Ematologia U	Torino	Italy	Not Yet Recruiting
Ospedale Cardinale G. Panico	Tricase	Italy	Not Yet Recruiting
Azienda Ospedaliera Universitaria Integrata - Ospedale Borgo Roma, Unità di Ematologia	Verona	Italy	Recruiting
Azienda ULSS 8 Berica - Ospedale San Bortolo, Divisione di Ematologia	Vicenza	Italy	Recruiting
Department of Hematology, University Hospital, Jagiellonian University Medical College	Krakow	Poland	Recruiting
Department and Clinic of Haematology, Blood Neoplasms, and Bone Marrow Transplantation, Wroclaw Medical University	Wroclaw	Poland	Recruiting
Department of Hematology and Bone Marrow Transplantation, Fundeni Clinical Institute	Bucharest	Romania	Recruiting
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) - Hospital Clinic	Barcelona	Spain	Recruiting
Hematology and Hemotherapy Department, 12 de Octubre University Hospital	Madrid	Spain	Recruiting

More FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS trials in Germany

A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes Recruiting

Other trials for the same condition

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis) Active, not recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral GB2064 in Participants With Myelofibrosis Active, not recruiting

Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Active, not recruiting

Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06533813 on ClinicalTrials.gov ↗ ← All trials in Germany